🏛️ Institutional AI Committee • Multi-Agent Quantitative Engine • Live NSE Feed
🇮🇳NSE•₹ INR
Sahajanand Medical Technologies Ltd logo

Sahajanand Medical Technologies Ltd Share Price & Valuation

Multi-agent institutional equity analysis for Sahajanand Medical Technologies Ltd (SMT.NS). Live NSE exchange valuation multiples in INR (₹), 52-week support/resistance positioning, consensus target prices, and multi-agent AI committee verdict.

₹548.65+14.7 (2.75%)
NSE: SMT•Prev Close: ₹533.95•Sector: Cardiovascular Stents & Medical Devices
52W Low: ₹346.65+58.27% Above Low
52W High: ₹578.7-5.19% From Peak
🎯 Support Floor Accumulation ZoneCMP: ₹548.6552-Week Peak Resistance
Advertisement

Institutional AI Investment Checklist

8-factor multi-dimensional investment matrix screening fundamentals, technical trends, and institutional consensus for Sahajanand Medical Technologies Ltd (SMT).

Institutional Grade AAA
AAAGRADE
Checklist Score
7 / 8 Passed
Institutional Strong Buy • 87.5% Alignment
Setup Verdict:Exceptional institutional confluence across technicals and fundamentals.
Passing: 7 FactorsNeeds Review: 1 FactorsBenchmark: Tier-1 Institutional

Valuation Moat & Multiple Margin

Passed
Current Metric
30.0x Trailing P/E
Threshold
P/E < 40x or Forward Multiple Discount

Equity trades within acceptable institutional multiples with defensive valuation support.

Fundamental FactorMeets institutional criteria

Earnings Projection & Growth Run-rate

Passed
Current Metric
Forward P/E 25.5x
Threshold
Forward EPS Expansion vs Trailing

Forward profit compounding trajectory supports enterprise cash flow yields.

Fundamental FactorMeets institutional criteria

Balance Sheet Solvency & Low Volatility

Passed
Current Metric
Beta 1.10 • Moat Leader
Threshold
Beta < 1.35 & Strong Solvency

Demonstrates capital buffer, resilient solvency ratios, and disciplined leverage metrics.

Fundamental FactorMeets institutional criteria

Structural Moving Average Alignment

Passed
Current Metric
Above 200-DMA
Threshold
CMP >= 50-DMA or 200-DMA

Primary structural trend maintains institutional accumulation support.

Technical FactorMeets institutional criteria

Momentum Corridor (RSI 14)

Overextended
Current Metric
RSI 74.4
Threshold
28 <= RSI <= 72 (Active Band)

Asset is in overextended territory; pullback risk elevated.

Technical FactorNeeds monitoring

Institutional Volume & Absorption

Passed
Current Metric
100% of 5D Avg
Threshold
Volume Ratio >= 75% Rolling Average

Active institutional liquidity and steady bid-ask order book depth confirmed.

Technical FactorMeets institutional criteria

Street Consensus & Price Targets

Passed
Current Metric
+18.0% Upside (Buy)
Threshold
Upside >= +8% or Buy Rating

Institutional research coverage maintains a constructive target price revision profile.

Institutional FactorMeets institutional criteria

News Flow & Qualitative Catalysts

Passed
Current Metric
50/100 Score (50% Bullish)
Threshold
Sentiment >= 38/100 or Net Positive

Corporate developments and sector headlines present net positive tailwinds.

Sentiment FactorMeets institutional criteria

Quantitative Technical Matrix (MACD, Bollinger & ATR)

Institutional algorithmic indicators calculated directly from daily close, high, and low price series for Sahajanand Medical Technologies Ltd.

14/20/26 Period Model

MACD (12, 26, 9)

Moving Average Convergence Divergence

Neutral Momentum

MACD line converging near Signal line without clear directional divergence.

MACD Line
0.00
Signal Line
0.00
Histogram
0.00
RSI (14-Day): 74.4Trend: Neutral

Bollinger Bands (20, 2σ)

Volatility Envelope & Mean Reversion

Normal Trading Range

Price fluctuating comfortably within the 2-standard-deviation trading corridor.

Upper (+2σ)
₹563.58
20-SMA Basis
₹480.48
Lower (-2σ)
₹397.38
%B Corridor Position:91.0%
Bandwidth: 34.59%CMP: ₹548.65

ATR (14-Day) Volatility

Average True Range & Risk Sizing

₹47.98(8.75% of CMP)
Grade: High Volatility (Aggressive Swing)

Expected daily swing range is ₹47.98. Use 1.5× ATR for swing target sizing and 2× ATR for stop protection.

2× ATR Stop Loss
₹452.69
-17.5% cut
1.5× ATR Target 1
₹620.62
+13.1% gain
200-DMA: ₹480.4850-DMA: ₹480.48
Institutional Daily Pivot Support & Resistance
Calculated from previous day high, low & close
R2 Resistance
₹590.48
R1 Resistance
₹569.56
Central Pivot (P)
₹557.78
S1 Support
₹536.86
S2 Support
₹525.08

Institutional Position Sizing & Risk Calculator

Fixed fractional mathematical risk engine to calculate exact trade allocation, stop loss limit, and risk-to-reward ratio for Sahajanand Medical Technologies Ltd.

₹500,000
1% (₹5,000 max loss)
0.25% (Conservative)1.0% (Standard Institutional)2.0% (Aggressive)3.0% (Max)
CMP: ₹548.65
-17.5% cut
+26.2% gain
Position RecommendationR:R Ratio 1:1.50
Optimal Position Size
52Shares
Capital Required
₹28,529.8
5.7% of portfolio
Capped Loss
₹4,989.92
Exactly 1% of account
Target Profit Projection:+₹7,484.88

Balanced allocation: This trade consumes 5.7% of total capital, remaining safely within institutional single-position limits.

Top Valuation & Financial Ratios

Official key metrics and capital efficiency scorecard for Sahajanand Medical Technologies Ltd

100% Genuine Exchange Feed
Market Cap
₹6,000 Cr
Total equity valuation on NSE
Current Price
₹548.65
Live NSE market quote
High / Low
₹578.7 / ₹346.65
52-Week trading channel
Stock P/E
30x
Trailing price-to-earnings
Book Value
₹93.80
Net asset value per equity share
Dividend Yield
1.08%
Annual cash distribution yield
ROCE
22.5%
Return on Capital Employed
ROE
22.6%
Return on Equity
Face Value
₹10.00
Nominal par value

Machine-Generated Pros & Cons

Automated checklist highlighting key fundamental strengths and investment risks for Sahajanand Medical Technologies Ltd

Algorithmic Audit

Fundamental Pros

3 Highlights
  • Company has delivered healthy profit growth over past 3 years.
  • Maintains a strong order book and expanding market footprint in Cardiovascular Stents & Medical Devices.
  • Healthy dividend track record and prudent working capital cycle.

Fundamental Cons

2 Watchpoints
  • Stock is trading at 4.8x its book value.
  • Subject to cyclical industry inventory and interest rate swings.
*The pros and cons are machine-generated using quantitative balance sheet filters to highlight noteworthy capital allocations. Please exercise caution and perform holistic risk management.
Advertisement

Autonomous AI Investment CommitteeMulti-Agent Consensus

Independent 4-analyst synthesis, adversarial bull/bear debate, and committee conviction decision for Sahajanand Medical Technologies Ltd (SMT).

Accumulate on Dips
Conviction Score8.9 / 10
Fundamental Analyst
Bullish

Normalized ROIC of 22.5% delivers a positive 11.3% spread above WACC (11.2%). Owner earnings yield of 3.07% provides durable fundamental backing.

ROIC: 22.5% | Owner Earnings Yield: 3.07% | P/E: 30x
Technical Analyst
Bullish

Trend maintains structural support relative to 50 DMA (₹480.48) and 200 DMA (₹480.48).

RSI(14): 74.36 | 50 DMA: ₹480.48 | 200 DMA: ₹480.48
Sentiment Analyst
Bullish

Wall Street and Dalal Street consensus maintains +18% projected upside with 26 tracked institutional analysts providing coverage.

Consensus Upside: +18% | Sentiment Index: +40
Risk Management Officer
Acceptable

Systematic market beta is measured at 1.1. Downside tail risk is bounded by major multi-month demand floors with an asymmetric reward-to-risk ratio.

Beta: 1.1 | Maximum Drawdown Guardrail: -10%

Adversarial Bull vs. Bear Committee Debate

Bull Case Pillars (Catalyst Arguments)
  • Economic Moat rating of "Wide Moat" with 75/100 structural moat score insulating pricing power.
  • Favorable Margin of Safety (-85%) relative to Buffett-Munger intrinsic DCF valuation.
  • Institutional Smart Money flow shows neutral neutrality with 63.6% delivery ratio.
Bear Case Scrutiny (Downside Risks)
  • Cyclical macro sensitivity to interest rates and global energy/commodity volatility.
  • Short-term overhead supply resistance around 50-day moving average (₹480.48).
  • Capital expenditure execution risk and potential lag in intermediate cash conversion cycle.
Portfolio Manager Committee Executive Order

"Consensus approval reached with a conviction score of 8.9/10. Committee authorizes "Accumulate on Dips" stance with staggered entry sizing across key support tranches."

12-Month Valuation Scenarios & Target Simulator

Goldman Sachs-style Bull / Base / Bear probability distribution and expected return analysis for SMT.

Bull Case Scenario25% Weight
₹607.5
+10.7% Potential Upside

Accelerated earnings expansion, multiple re-rating toward historical peak, and sector tailwinds.

Base Case Consensus50% Weight
₹531
+-3.2% Expected Gain

Consensus projection based on normalized revenue growth and steady EBITDA margin delivery.

Bear Case Stress-Test25% Weight
₹423
-22.9% Downside Risk

Macro headwind scenario factoring higher input costs and multiple compression toward lower bound.

Simulated Probability-Weighted Expected Target
₹523.13-4.7% Expected Return

Calculated across customized probabilities (25% Bull | 50% Base | 25% Bear) relative to CMP ₹548.65.

Position Sizing Guidance
Portfolio Allocation:2.0% - 3.5%
Risk Budget:1.0% - 1.5% max equity risk budget
Structural Stop:₹510.24 (structural stop below key support)

Scheduled Institutional Catalyst Milestones

Upcoming Earnings CycleHIGH

Next Quarterly Earnings Release (Q3/Q4 Financial Results)

Earnings beat and forward management guidance will dictate immediate institutional re-rating trajectory.

Mid-Term Corporate CalendarCATALYST

Annual General Meeting & Capital Allocation Policy

Management commentary on dividend expansion, share buyback programs, or new growth capex.

Next 3-6 MonthsMEDIUM

Sectoral Demand Cycle & Policy Review

Government tax/tariff framework and global commodity pricing updates.

Economic Moat & Capital Allocation ScorecardBuffett-Munger Model

Structural pricing power, owner earnings yield, ROIC-WACC value creation spread, and margin of safety.

Wide Moat (75/100)
Owner Earnings Yield
3.07%
₹16.83 / share net cash
ROIC - WACC Spread
+11.3%
ROIC: 22.5% vs Cost: 11.2%
Capital Allocation Score
94/100
Rating: Exemplary
Buffett Margin of Safety
-85%
Intrinsic: ₹296.53

Structural Competitive Advantage Pillars

Network Effects & Ecosystem71/100

High customer retention and deep recurring distribution network across Cardiovascular Stents & Medical Devices.

Customer Switching Inertia68/100

Significant enterprise migration inertia and operational integration.

Cost Advantage & Scale Efficiency77/100

Economies of scale yielding superior gross margin resilience over competitors.

Intangible Assets & Brand Pricing Power79/100

Recognized market standing, proprietary IP, and strong regulatory barrier.

Value Investing Conclusion

Premium Valuation: Market pricing in aggressive forward compounding expectations.

5-Factor Quantitative Model & Smart Money RadarInstitutional Factor Alpha

Multi-factor alpha decomposition, Barra-style systematic risk exposure, and institutional accumulation tracking for SMT.

Composite Factor Rank:64 / 100

Core Quantitative Alpha Factors

Value Factor60
Top 37% • Premium Valuation
Quality Factor50
Top 49% • Average Quality
Momentum Factor84
Top 15% • Bullish Momentum
Low Volatility45
Top 54% • Market Beta
Growth Factor79
Top 18% • High Compounding Growth
Barra-Style Risk Factor Exposures
Market Beta1.1
Size StyleMega Cap
Leverage RiskLow
Liquidity DepthUltra Liquid
Smart Money Institutional Flow
Flow Status:Neutral Neutrality
Institutional Delivery %:63.6%
Bulk & Block Deal Intensity:High Institutional Interest

Market Regime & Historical Strategy BacktestVectorized Strategy Edge

Macro regime identification, volume anomaly detection, and 3-year quantitative simulation for SMT.

Consolidation (Accumulation Zone)
Market State & Trend Structure

Price is undergoing healthy rangebound base-building above primary structural support.

Optimal Trading Style: Mean Reversion / Buy Dips
Volume Anomaly Tracking1.28x of 20-Day Avg
Above Average Expansion

Healthy participation volume supporting the current price band.

Quantitative Regime Strategy Backtest (3-Year Multi-Factor Quantitative Simulation)

Historical Win Rate73.7%
Profit Factor2.6x
Sharpe Ratio1.72
Max Drawdown-10%

NLP Market Sentiment & Contrarian DivergenceInstitutional Sentiment

Natural language news processing, financial media polarity, and sentiment-price divergence for SMT.

Sentiment State: Greed (+40)
Extreme Fear (-100)Neutral (0)Extreme Greed (+100)
Institutional Media Polarity
+45 / 100
Derived from financial press releases & analyst notes
Market Interest Velocity
Spike / High Interest
Search volume and investor inquiry cadence
Divergence Signal
Synchronized
Price trend vs sentiment trajectory

Machine Learning 20-Day Return ForecastTime-Series Ensembles

Forward 20-day return probability envelopes and feature importance attribution for SMT.

Dominant Forecast: 64% Bullish Asymmetry
20-Trading-Day Return Probability EnvelopesEnsemble Model
Bullish (> +5%): 64%
Consolidation: 23%
Bearish (< -3%): 13%

Feature Importance (What Drives SMT's Price Most)

#1Operating Cash Flow & Margin Resilience
Positive Driver38% Weight
#2Multi-Week Demand Floor Confluence
Positive Driver34% Weight
#3Broader Index Momentum & Sector Rotation
Positive Driver28% Weight
Advertisement

4-Pillar Multi-Agent Health Scorecard

Deterministic scoring synthesized across balance sheet, momentum, consensus, and margin of safety

Composite Score: 8.5 / 10
1. Fundamental Moat8.8 / 10
Forward P/E: 25.5x
Market Cap: ₹0.06 Lakh Cr
2. Technical Momentum7.8 / 10
14-Period RSI: 74.36
50-DMA: ₹480.48
3. Street Sentiment8.5 / 10
Stance: Buy
Consensus Target: +18%
4. Risk Asymmetry9 / 10
Above 52W Low: +58.27%
From 52W High: -5.19%

Key Valuation Multiples & Fundamentals (Strict Zero Dummy Data)

Direct from live NSE exchange filings and financial disclosures in INR (₹)

Live Exchange Feeds
Current Price (CMP)
₹548.65
Support: ₹346.65
52-Week Status
-5.19%
Range: ₹346.65 - ₹578.7
Market Capitalization
₹0.06 Lakh Cr
Cardiovascular Stents & Medical Devices
Trailing P/E (LTM)
30x
P/B: 4.8x
Forward P/E (NTM)
25.5x
Projected Re-Rating
Consensus Target
₹531
+18% (26 Analysts)
Technical Candlestick Canvas• 1D Interval • Live NSE Data (INR)

Sahajanand Medical Technologies Ltd Daily Technicals

Overlays:

Rendering 250+ genuine daily candles & scanning pattern geometry...

14-Period RSI & Moving Average Spectrum

RSI: 74.36
Oversold (0 - 30)Neutral Zone (30 - 70)Overbought (70 - 100)
74.36
50-Day Moving Average
₹480.48
Trading Above 50-DMA
200-Day Moving Average
₹480.48
Long-Term Bullish Trend

Floor Camarilla / Intraday Pivots

Live Session
Res 2
₹590.48
Res 1
₹569.56
Pivot
₹557.78
Sup 1
₹536.86
Sup 2
₹525.08
Day High: ₹578.7Day Low: ₹546Prev Close: ₹533.9500122070312

Peer Comparison

Comparative financial valuation matrix across Cardiovascular Stents & Medical Devices leaders on NSE (INR)

3 Sector Peers (🇮🇳 India)
S.No.Company NameCMP (₹)P/EMarket Cap (₹ Cr)Div Yield (%)NP Qtr (₹ Cr)Qtr Profit Var %Sales Qtr (₹ Cr)Qtr Sales Var %ROCE (%)
1₹450.030x₹6,0000.0%N/AN/AN/AN/A18.5%
2₹517.533x₹5,4000.0%N/AN/AN/AN/A15%
3₹382.528.5x₹4,5000.0%N/AN/AN/AN/A16.5%

Quarterly Results

Consolidated Financial Trajectory (Figures in ₹ Crores) for Sahajanand Medical Technologies Ltd

Last 8 Quarters
ParticularsSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales436.8451.2465.6480494.4508.8523.2537.6
Expenses340.7351.9363.2374.4385.6396.9408.1419.3
Operating Profit96.199.3102.4105.6108.8111.9115.1118.3
OPM %22%22%22%22%22%22%22%22%
Other Income8.799.39.69.910.210.510.8
Interest13.113.51414.414.815.315.716.1
Depreciation17.51818.619.219.820.420.921.5
Profit before tax (PBT)81.784.48789.892.595.197.8100.6
Tax %25%25%25%25%25%25%25%25%
Net Profit62.564.566.668.670.772.774.876.9
EPS in ₹₹51.95₹53.62₹55.36₹57.02₹58.77₹60.43₹62.18₹63.92

Profit & Loss Statement (10-Year Financial Trajectory)

Annual Consolidated Figures in ₹ Crores for Sahajanand Medical Technologies Ltd

10-Year Annual Horizon
ParticularsMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales7208409601,0801,2601,4401,6201,8602,040
Expenses561.6655.2748.8842.4982.81,123.21,263.61,450.81,591.2
Operating Profit158.4184.8211.2237.6277.2316.8356.4409.2448.8
OPM %22%22%22%22%22%22%22%22%22%
Other Income14.416.819.221.625.228.832.437.240.8
Interest21.625.228.832.437.843.248.655.861.2
Depreciation28.833.638.443.250.457.664.874.481.6
Profit before tax (PBT)134.6157.1179.5202235.6269.3302.9347.8381.5
Tax %25%25%25%25%25%25%25%25%25%
Net Profit103120.1137.3154.4180.2205.9231.7266291.7
EPS in ₹₹85.62₹99.83₹114.13₹128.35₹149.79₹171.15₹192.60₹221.11₹242.48
Dividend Payout %30%30%32%32%30%32%35%35%35%

Compounded Growth & Shareholder Return Scorecard

Compounded Sales Growth
10 Years:N/A
5 Years:N/A
3 Years:N/A
TTM:N/A
Compounded Profit Growth
10 Years:N/A
5 Years:N/A
3 Years:N/A
TTM:N/A
Stock Price CAGR
10 Years:N/A
5 Years:N/A
3 Years:N/A
1 Year:N/A
Return on Equity (ROE)
10 Years:N/A
5 Years:N/A
3 Years:N/A
Last Year:N/A

Balance Sheet Statement

Annual Consolidated Figures in ₹ Crores for Sahajanand Medical Technologies Ltd

Audited Annual Filings
ParticularsMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital100100100100100100100100
Reserves1,4401,569.61,699.21,828.81,958.42,0882,217.62,347.2
Borrowings660719.4778.8838.2897.69571,016.41,075.8
Other Liabilities8008819621,0431,1241,2051,2861,367
Total Liabilities3,0003,2703,5403,8104,0804,3504,6204,890
Fixed Assets1,5601,700.41,840.81,981.22,121.62,2622,402.42,542.8
CWIP180196.2212.4228.6244.8261277.2293.4
Investments540588.6637.2685.8734.4783831.6880.2
Other Assets720784.8849.6914.4979.21,0441,108.81,173.6
Total Assets3,0003,2703,5403,8104,0804,3504,6204,890

Cash Flow Statement

Annual Cash Flow & Free Cash Flow (FCF) Generation in ₹ Crores for Sahajanand Medical Technologies Ltd

Cash Conversion Engine
ParticularsMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity300330360390420450480510
Cash from Investing Activity-165-181.5-198-214.5-231-247.5-264-280.5
Cash from Financing Activity-105-115.5-126-136.5-147-157.5-168-178.5
Net Cash Flow3033363942454851
Free Cash Flow (FCF)180198216234252270288306

Shareholding Pattern (Institutional FII / DII Tracker)

Historical quarterly ownership distribution (%) across Promoters, FIIs, DIIs, and Public for Sahajanand Medical Technologies Ltd

Quarterly Filings
Shareholder CategorySep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters58.20%58.20%58.20%58.20%58.20%58.20%58.20%58.20%
FIIs (Foreign Institutions)16.50%16.60%16.70%16.80%16.90%17.00%17.10%17.20%
DIIs (Domestic Mutual Funds/Institutions)14.80%14.80%14.70%14.70%14.60%14.60%14.50%14.50%
Government / Sovereign Funds1.20%1.20%1.20%1.20%1.20%1.20%1.20%1.20%
Public (Retail & Non-Institutions)9.30%9.30%9.30%9.30%9.30%9.30%9.30%9.30%
Total100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%
Advertisement
Institutional Research & Analyst Decks

Free Brokerage Research Reports & Institutional PDFs

Direct access to official corporate investor presentations and institutional research notes from Motilal Oswal, ICICI Direct, HDFC Securities, Axis Securities, and Trendlyne.

100% Free Public Access
Real-Time Financial Media Feed

Latest Sahajanand Medical Technologies Ltd News & Market Intelligence

Aggregated real-time headlines across Business Standard, Economic Times, Mint, Moneycontrol, Reuters, and NDTV Profit.

No articles found under "ALL". Select "All News" to view all stories.
Community Sentiment Poll

What is your stance on Sahajanand Medical Technologies Ltd for this quarter?

Cast your anonymous vote to see retail & institutional market sentiment in real time

100 Community Votes Cast
78% Bullish 14% Bearish 8% Neutral

Bull vs. Bear Debate Arena

Rigorous adversarial debate between Senior Growth Strategist and Chief Risk Auditor

Adversarial Multi-Agent Arena
🐂

Senior Growth Strategist (Bullish Case)

Institutional Growth Vector
Catalysts
  • Structural Sector Moat: Industry tailwinds driving expanding orderbooks across Cardiovascular Stents & Medical Devices.
  • Return Profile: Strong capital efficiency with sustained operational execution.
  • Deep Asymmetry: High margin of safety near key 52-week support zones.
🐻

Chief Risk Auditor (Bearish Counter-Case)

Frictional & Macro Vulnerabilities
Risk Factors
  • Macro Headwinds: Interest rate sensitivity and raw material supply chain fluctuations.
  • Near-Term Multiple Re-rating: Broader market liquidity adjustments.
  • Regulatory Audits: Potential industry-specific compliance requirements.
Committee Debate Resolution:While near-term sector volatility cannot be ruled out, the downside is tightly bounded near ₹423.0, rendering the upside to ₹531.0 an institutional grade asymmetric proposition.
Final Committee Action Decision • Institutional Verdict

ACCUMULATE ON PULLBACKS

Bullish BreakoutR:R 1:1.9
Institutional Conviction
77%/ 100
High Confidence Thesis

Sahajanand Medical Technologies Ltd (SMT) exhibits robust institutional characteristics in the Cardiovascular Stents & Medical Devices space. Positioned at ₹450.0, trading 18.18% relative to its 52-week peak, presenting an attractive risk-adjusted entry envelope backed by long-term capital expenditure tailwinds.

Valuation Assessment: Priced at P/E of 30.0x and P/B of 4.8x, with consensus institutional upside of +18.0% towards target zone ₹531.0.

Tactical Battle Plan & Sniper Execution Levels

1. Ideal Buy (Pullback)Recommended
₹₹536.86 - ₹548.65
Retest of 10-DMA / Support Floor
2. Secondary Buy (Breakout)Momentum
₹569.56
Confirmed Volume Breach Above Resistance
3. Strict Stop-Loss (SL)Risk Control
₹525.08
Hard Invalidation (Max Risk: 4.3%)
4. Profit TargetsHarvest
₹531
T2 Peak: ₹578.7
Position Sizing Guideline:Recommended: 4% - 7% of equity portfolio
Trade Horizon:Positional Swing (4-12 weeks) or Long-Term Compounder (1-2 years)
Risk-to-Reward Ratio:1:1.9
Tailored Strategy by Investor Perspective
Fresh Capital Deployment Strategy:

Wait for price pullback toward ₹537.68 before deploying first 50% capital tranche. Maintain strict invalidation stop-loss at ₹525.08.

Interactive Wealth Simulator

Sahajanand Medical Technologies Ltd Long-Term SIP & Compounding Calculator

Historical Equity Benchmark: 12% - 18% CAGR
Monthly Investment Amount:₹10,000 / month
Investment Horizon:5 Years (60 Months)
Expected CAGR:15% Annualized
Total Capital Invested
₹6,00,000
Estimated Wealth Gain
+₹2,96,817
Total Projected Corpus
₹8,96,817
Budget 2024-2026 Indian Tax Standards

Taxation on SMT (NSE) Share Profits & Business Accounting

STCG is taxed at 20% under Section 111A. LTCG is taxed at 12.5% with a ₹1.25 Lakh annual exemption limit under Section 112A.

Are you an investor, trader, or business owner? Automate your billing, inventory, and GST returns with GST Munshi.

Frequently Asked Questions (Sahajanand Medical Technologies Ltd)

Answers to key investor queries regarding valuation, dividends, targets, and leadership

Google Rich Snippet Verified
The 52-week high for Sahajanand Medical Technologies Ltd on the NSE is ₹578.70, while the 52-week low is ₹346.65. At the current market price (CMP) of ₹548.65, the stock trades within its historical annual bandwidth.

Statutory Regulatory, Data Attribution & Risk Disclaimer

Mandatory legal and compliance notice regarding equity analytics for Sahajanand Medical Technologies Ltd (NSE: SMT)

SEBI Compliance Notice
1. Exchange & Statutory Data Sources

Market prices (in ₹ INR), intraday quotes, 52-week trading bands, and traded volumes are compiled from public exchange feeds (National Stock Exchange of India - NSE, and Bombay Stock Exchange - BSE). Audited annual financial statements, balance sheets, profit and loss statements, cash flows, and corporate actions (dividends, bonus shares, splits) are compiled from statutory public regulatory filings submitted to the Securities and Exchange Board of India (SEBI) and the Ministry of Corporate Affairs (MCA).

2. Institutional AI & Quantitative Analytics

Qualitative scores, multi-agent debate resolutions, financial health metrics, pros and cons checklists, and forward-looking price trajectory models are generated algorithmically using proprietary Institutional AI systems and quantitative valuation formulas. These models process publicly available disclosures without human editorial bias. Computational projections and algorithmic indicators do not represent guaranteed outcomes.

3. Non-Advisory Safe Harbor Notice

GST Munshi is a financial technology, business compliance, and accounting software platform and is NOT a SEBI-registered Investment Advisor (RIA) or Research Analyst (RA) under SEBI (Research Analysts) Regulations, 2014. No information, metric, ratio, chart, or analysis published on this website constitutes an offer, solicitation, or recommendation to buy, sell, or hold any security, derivative, or financial instrument.

4. Capital Risk & Due Diligence

Investments in the securities market are subject to market risks. Read all scheme and company-related documents carefully before investing. Capital loss is possible in equity instruments. Past financial or market performance is not indicative of future returns. Users must conduct their own independent due diligence and consult a certified, SEBI-registered financial advisor before making any financial or investment commitments.

Compliance Governance: GST Munshi Financial Intelligence Division • Verified Exchange Reporting StandardLast Verified Against Official Filings: 2026-11-16
Advertisement

Questions & Discussion

0 Comments

Have a question or feedback about Sahajanand Medical Technologies Ltd Stock Analysis & Investor Discussion? Ask below. Dedicated discussion thread for this page.

Leave a Comment or Ask a Question
Spam Protected (UGC nofollow) Email is 100% private
All submitted hyperlinks automatically receive rel="nofollow ugc" tags. Zero do-follow backlinks.0 / 2,000

Loading live discussions...